295 related articles for article (PubMed ID: 27103403)
1. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
3. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
5. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
Yang RK; Zhao P; Lu C; Luo J; Hu R
Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type.
Hsieh MS; Lee YH; Jin YT; Kuo YJ
Virchows Arch; 2020 Oct; 477(4):581-592. PubMed ID: 32383006
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
8. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
[TBL] [Abstract][Full Text] [Related]
9. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.
Nakaguro M; Tada Y; Faquin WC; Sadow PM; Wirth LJ; Nagao T
Cancer Cytopathol; 2020 Oct; 128(10):693-703. PubMed ID: 32421944
[TBL] [Abstract][Full Text] [Related]
10. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Nardi V; Sadow PM; Juric D; Zhao D; Cosper AK; Bergethon K; Scialabba VL; Batten JM; Borger DR; Iafrate AJ; Heist RS; Lawrence DP; Flaherty KT; Bendell JC; Deschler D; Li Y; Wirth LJ; Dias-Santagata D
Clin Cancer Res; 2013 Jan; 19(2):480-90. PubMed ID: 23186780
[TBL] [Abstract][Full Text] [Related]
11. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
12. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Chiosea SI; Thompson LD; Weinreb I; Bauman JE; Mahaffey AM; Miller C; Ferris RL; Gooding WE
Cancer; 2016 Oct; 122(20):3136-3144. PubMed ID: 27379604
[TBL] [Abstract][Full Text] [Related]
13. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
14. The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
Urano M; Hirai H; Tada Y; Kawakita D; Shimura T; Tsukahara K; Kano S; Ozawa H; Okami K; Sato Y; Fushimi C; Shimizu A; Takase S; Okada T; Sato H; Imanishi Y; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Sato Y; Saigusa N; Nakaguro M; Hanazawa T; Nagao T
Histopathology; 2018 Dec; 73(6):943-952. PubMed ID: 29993139
[TBL] [Abstract][Full Text] [Related]
15. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
[TBL] [Abstract][Full Text] [Related]
16. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
17. Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?
Rooper LM; Gagan J; Bishop JA
Head Neck Pathol; 2022 Dec; 16(4):1063-1072. PubMed ID: 35794510
[TBL] [Abstract][Full Text] [Related]
18. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
19. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma.
Hoang MP; Callender DL; Sola Gallego JJ; Huang Z; Sneige N; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2001 Oct; 19(4):865-71. PubMed ID: 11562768
[TBL] [Abstract][Full Text] [Related]
20. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.
Dogan S; Ng CKY; Xu B; Kumar R; Wang L; Edelweiss M; Scott SN; Zehir A; Drilon A; Morris LGT; Lee NY; Antonescu CR; Ho AL; Katabi N; Berger MF; Reis-Filho JS
Hum Pathol; 2019 Jun; 88():66-77. PubMed ID: 30946933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
